Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

Who Took Part

The study group was 90 subjects.

By PubMed's age tags, the people studied were adults, men only.

This was a multicenter randomized double-blind crossover study of 90 male subjects with type 1 diabetes.

Each 4-week study period ended with a 24-h inpatient serum insulin and plasma glucose profile.

How the Study Was Run

The researchers set it up as a randomized, double-blind, crossover and multicenter study.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the subjects and researchers unaware of who received Insulin Aspart.

In the crossover set-up each of the subjects took both Insulin Aspart and the comparison in turn, acting as their own control.

More than one site took part, so the subjects came from several places.

Insulin aspart or soluble human insulin was administered before meals, and NPH insulin was administered at bedtime as basal therapy.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Glucose Self-Monitoring, Circadian Rhythm, Diabetes Mellitus, Type 1, Fructosamine, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 90 subjects.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Aspart compound page, all human trials.